Ym1 protein crystals promote type 2 immunity
- Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Belgium
- Department of Internal Medicine and Pediatrics, Ghent University, Belgium
- Unit for Structural Biology, VIB-UGent Center for Inflammation Research, Belgium
- Department of Biochemistry and Microbiology, Ghent University, Belgium
- Department of Pulmonary Medicine, Erasmus University Medical Center Rotterdam, Netherlands
Figures
Figure 1
Recombinant Ym1 and Ym2 crystals are structurally similar to in vivo Ym1 and Ym2 crystals and to each other.
(A, B) Light microscopy pictures of recombinant Ym1 (A) and Ym2 (B) crystals. (C–E) Structural superposition of the X-ray structures determined from a native in vivo grown Ym1 crystal isolated from the BAL fluid of mev/mev mice (C+E) (yellow), a native in vivo grown Ym2 crystal isolated from the BAL fluid of a C57BL/6J-Tg(CAG-Gal10)Bla mouse (D+E) (blue) and a recombinant Ym1 (C) and Ym2 (D) crystal (grey). The low root-mean-square deviations (RMSDs) establish structural similarity. (F, G) Crystal packing of ex vivo Ym1 (F) and Ym2 (G) crystals revealing their crystallographic equivalence.
Figure 2
Ym1 crystals activate innate immunity.
(A) Scheme representing the innate immune response experiment. (B) Flow cytometric analysis of the immune cell influx in the lungs of PBS, Ym1 crystal and soluble Ym1 treated mice measured 6 and 24 hr after i.t. injection. Data are pooled from 2 (for 6 hr time point) or 3 (for 24 hr time point) independent experiments with n=13, 13, 13, 14, 15 and 15, respectively. (C) Concentration of IL-6 and TNFα in the BAL fluid measured by ELISA. (D, E) Concentration of IL-1β, IL-33 (D), CCL2 and CCL24 (E) per milligram of protein of dispersed lung tissue measured by ELISA. Data are pooled from two independent experiments with n=13 per group. Data are shown as mean ± SEM. ns p≥0.05; *p<0.05; **p<0,01; ***p<0.001; ****p<0.0001. (F) ImageStream pictures of the BAL fluid of Ym1 crystal and soluble Ym1 treated mice 6 and 24 hr after i.t. injection. Samples were stained with an antibody recognizing Ym1/2 (red).
Figure 3
Ym1 crystals activate DCs in the lymph nodes.
(A) Gating strategy to distinguish different subsets of DCs and recruited monocytes. (B) Scheme representing the DC activation experiment. (C, D) Flow cytometric analysis of the DC and monocyte influx in the mLNs of PBS, OVA-AF488 alone, OVA-AF488 plus Ym1 crystals and OVA-AF488 plus soluble Ym1 treated mice measured 24 hr after i.t. injection. (E) Median Fluorescence Intensity (MFI) of activation marker CD86 on OVA-AF488 +cDC1 s and cDC2s of PBS, OVA-AF488 alone, OVA-AF488 plus Ym1 crystals and OVA-AF488 plus soluble Ym1 treated mice measured 24 hr after i.t. injection. Data are pooled from 2 independent experiments with n=10 mice per group. Data are shown as mean ± SEM. ns p≥0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
Figure 4
Ym1 crystals boost adaptive cellular immunity.
(A) Scheme representing the used adoptive transfer model. (B–E) Proliferation and KN2 expression of OT-II T cells in the mLNs and lungs 4 and 7 days after i.t. administration of PBS, OVA alone, OVA plus Ym1 crystals or OVA plus soluble Ym1. (B) Representative histograms of the division profile of the adoptively transferred OT-II T cells (CD3e+ CD4+ Vα2+ CD45.1.2+) in the mLNs on day 4. (C, D) The numbers of OT-II T cells and KN2 +OT II T cells in the mLNs on day 4 (C) and day 7 (D). (E) The numbers of OT-II T cells and KN2 +OT II T cells in the lungs on day 7. Data are pooled from two independent experiments with n=10 mice per group. Data are shown as mean ± SEM. ns p≥0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
Figure 5
Ym1 crystals can act as type 2 adjuvant in OVA-induced asthma model and activate adaptive humoral immunity.
(A) Scheme representing the used OVA-induced asthma model. (B) Flow cytometric analysis of the immune cell influx in the BAL fluid of mice sensitized i.t. with PBS, OVA alone, OVA plus Ym1 crystals or OVA plus soluble Ym1 and challenged i.n. with OVA. Data are pooled from two independent experiments with n=18 per group. (C) Levels of IL-5, IL-10, and IL-13 in the supernatant of mLN cells after restimulation with OVA for 20 hr. Data are from 1 experiment with n=5, 7, 9 and 9, respectively. (D) Serum OVA-specific IgG1 antibodies were measured by ELISA. (E) Serum Ym1-specific IgM antibodies were measured by ELISA. Data are pooled from two independent experiments with n=18 per group. (F) Scheme representing the adaptive humoral immune response experiment. (G) Serum Ym1-specific IgM antibodies were measured by ELISA. Data are pooled from three independent experiments with n=13, 13, 9, 9, 12, and 8, respectively. Data are shown as mean ± SEM. ns p≥0.05; *p<0.05; **p<0.01; ****p<0.0001. If pairwise comparison is not shown, the result is not significant.
Additional files
-
Supplementary file 1
Crystallographic data and refinement statistics.
Key crystallographic data of ex vivo isolated Ym1 and Ym2 crystals for comparison with in vitro generated recombinant Ym1 and Ym2 crystals. Each dataset was collected from a single crystal. Values in parentheses are for highest-resolution shell.
- https://cdn.elifesciences.org/articles/90676/elife-90676-supp1-v1.docx
-
MDAR checklist
- https://cdn.elifesciences.org/articles/90676/elife-90676-mdarchecklist1-v1.docx
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Ym1 protein crystals promote type 2 immunity
eLife 12:RP90676.
https://doi.org/10.7554/eLife.90676.3
